About this digest
About Telehealth CJC-1295
An independent, accessibility-first reading of the CJC-1295 research record — what the studies measured, and where this peptide actually stands.
What this site is
Telehealth CJC-1295 is an independent editorial project that publishes plain-language summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site is built as an accessibility-first public-information resource: hierarchy that survives in grayscale, plain-language status labels, and a clear separation between what the literature established and what it leaves open. The aim is a reader treated with the dignity of a trusted information sheet, not a hype page.
About the name
The word "telehealth" in this site's name is editorial framing — a register, not a service. It signals the measured, public-information voice a responsible health-information resource would use when summarizing research. It is not a claim that this site offers telehealth, consultations, prescriptions, diagnosis, or any clinical service. There is no clinic behind the name and no counter behind the page.
That distinction matters because CJC-1295 is an unapproved research chemical with no approved human indication anywhere, reviewed and not recommended for compounding at the 2024 FDA Pharmacy Compounding Advisory Committee, and prohibited at all times in sport under WADA Section S2 [13][15]. A site about a compound with that standing has a duty to be exact about what it is and is not.
How we handle the evidence
Every quantitative claim on this site is tied to a specific source on the full reference list. We distinguish human findings from animal and in-vitro work, and we mark honest gaps — the absence of a large human safety dataset, the discontinued long-acting program — as plainly as we report the established pharmacokinetics. Where the public record is uncertain, as with the development-era patient death cited in connection with the halted DAC trial, we say so rather than smoothing it over.
We also keep the DAC and no-DAC forms distinct throughout, because conflating them is the most common error in the popular literature and it changes how every kinetic finding should be read. The goal is a digest a careful reader can trust precisely because it does not overstate: it leads with what the studies measured, attributes each number to its study, and leaves the open questions visibly open.